Table 5 Results of sensitivity analyses

Main results

790

1.96

1.10

3.12

578

2.01

1.02

3.42

203

2.02

0.47

4.77

 ABM doses

 Doses lagged by 1 year

790

1.99

1.13

3.16

578

2.04

1.05

3.47

203

2.07

0.54

4.80

 Doses lagged by 5 years

790

1.06

0.45

1.82

578

1.25

0.53

2.20

203

0.60

−0.43

2.20

 Use of median of dose realizations instead of mean

790

2.08

1.09

3.42

578

2.13

0.99

3.75

203

2.17

0.36

5.35

 99th percentile

777

3.17

1.90

4.91

567

3.02

1.59

5.09

201

3.81

1.43

8.20

 98th percentile

761

3.54

2.08

5.55

554

3.27

1.66

5.63

198

4.43

1.67

9.62

 95th percentile

710

2.80

1.27

4.94

520

2.79

1.02

5.41

181

2.88

0.34

7.75

 5 years from first CT

524

2.36

1.21

4.05

381

2.54

1.19

4.66

139

1.74

0.05

5.25

 10 years from first CT

261

2.67

1.02

5.69

185

3.12

1.13

7.08

72

1.28

-0.62

8.11

 Individuals born before the start of cancer registration

490

1.54

0.68

2.80

365

1.59

0.60

3.14

119

1.84

0.20

5.29

 Hospitals with low reporting consistency

603

1.93

0.97

3.29

440

2.17

1.00

3.93

158

1.49

0.00

4.31

 Follow-up 2 years after country-specific maximum age at exposure

491

1.27

0.49

2.39

356

1.26

0.39

2.63

128

1.61

0.11

6.61

 Individuals with no vital status

739

1.73

0.89

2.97

541

1.91

0.91

3.35

189

1.39

0.03

3.85

United Kingdom—main results

NA

276

2.77

1.12

5.55

NA

 Excluding individuals who underwent transplant

NA

256

2.57

0.97

5.31

NA